β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer

• Main Authors: Mengjie Wang (Author), Yu Bai (Author), Jiaxin Pei (Author), Dongqing Li (Author), Xiaolin Pu (Author), Wenyu Zhu (Author), Lei Xia (Author), Chunjian Qi (Author), Hua Jiang (Author), Yongling Ning (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) checkpoint blocking antibodies have been shown to be a powerful immune checkpoint blockade (ICB) therapy for patients with cancer. However, patients quickly develop resistance to immunotherapy. β-glucan, an immune adjuvant, has been found to stimulate in...